Peptide News Digest

Oral GLP-1 Tracker — Wegovy Pill First Decline + Foundayo Week 5 +40%, Lilly Analyst Outlook, Nature Biotech TCR PRP, ASCO 2026 in Four Days

Wegovy pill scripts decline for first time, Foundayo Week 5 +40%, Lilly analyst targets, Nature Biotech TCR PRP paper, retatrutide TRIUMPH timing, ASCO 2026.

10 stories · Covering industry, research, clinical-trials

Editor's Note

Sunday digest anchored on Friday's Fierce Pharma Oral GLP-1 Tracker, which flagged the first weekly decline in Wegovy pill prescriptions since the January 5 launch — scripts dropped from ~143,000 to ~137,000 in the week ending May 8 — even as total Wegovy (injectable + pill) scripts climbed 1.3% to ~446,000 with a 40.5% obesity GLP-1 market share. Foundayo Week 5 IQVIA hit 10,248 prescriptions, a 40% week-over-week jump that finally narrows the trajectory gap with Novo's oral semaglutide. Wall Street's mid-May Lilly outlook is firmly bullish: Barclays $1,400 (Overweight, tirzepatide momentum), Cantor Fitzgerald $1,230 (Overweight, Foundayo + Mounjaro), and Motley Fool's May 17 piece framed Lilly's next-generation retatrutide as the agent that could 'waylay Wegovy and even zap Zepbound' once TRIUMPH-1 and TRIUMPH-2 read out in Q2-Q3 2026. The cardiovascular outcomes trial TRIUMPH-OUTCOMES isn't expected until 2027, but the seven other Phase 3 readouts due this year remain the largest near-term catalyst for the company. On the non-GLP-1 side, a Nature Biotechnology paper from a multi-institution collaboration introduced deep peptide recognition profiling (PRP) — a yeast-display and protein-language-model platform that decodes TCR specificity across HLA-B*27:05-restricted ankylosing spondylitis and acute anterior uveitis TCRs, identifying autoantigen candidates that AlphaFold3 missed. A 2026 Discover Oncology review consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics, joining the Frontiers in Medicine April review and the May International Journal of Peptide Research piece. The AMR-breakthrough wave — AI-designed AMPs, phage therapy, repurposed drugs — has produced peer-reviewed evidence supporting peptides as the most promising near-term antibiotic-resistance response. ASCO 2026 abstracts drop in four days (May 21) with the peptide oncology slate dominated by Bicycle Therapeutics, Avacta, Pfizer, BioVaxys, BriaCell, and the Crinetics CRN09682 SSTR2 NDC.

Industry

Oral GLP-1 Tracker (Fierce Pharma May 15-16): Wegovy Pill Scripts Decline for First Time Since January Launch; Foundayo Week 5 +40% W/W to 10,248

Fierce Pharma's Oral GLP-1 Tracker reported the first weekly decline in Wegovy pill prescriptions since the January 5, 2026 launch: scripts dropped from ~143,000 to ~137,000 in the week ending May 8. Total Wegovy (injectable + pill) scripts climbed 1.3% w/w to ~446,000, taking obesity GLP-1 market share to 40.5%. Eli Lilly's Foundayo posted Week 5 IQVIA prescriptions of 10,248, up 40% w/w from Week 4's 7,335 — the steepest weekly growth in the launch series, attributed to mid-May commercial access activation at two of the three largest US PBMs. The cumulative US Wegovy pill user count crossed 1 million per Novo CEO Doustdar's May 14 commentary; the Wegovy injectable continues to be the largest US GLP-1 single-product line. The Wegovy pill plateau and Foundayo acceleration narrow the trajectory gap that has defined the oral-GLP-1 race since April.

#wegovy-pill #foundayo #oral-glp-1 #iqvia #fierce-pharma #tracker #market-share
Industry

Eli Lilly Mid-May Analyst Consensus: Barclays $1,400, Cantor Fitzgerald $1,230, Motley Fool $1,085 Targets on Tirzepatide + Foundayo Momentum

Wall Street's mid-May Lilly outlook is firmly bullish. Barclays analyst Emily Field raised her LLY price target to $1,400 from $1,350 (Overweight) citing tirzepatide momentum and the easing concerns around Foundayo's launch trajectory. Cantor Fitzgerald lifted its target to $1,230 with an Overweight rating on Mounjaro demand and Foundayo PBM coverage activation. Motley Fool's May 17 commentary settled on $1,085 with a buy rating and 70% confidence, citing the company's raised 2026 guidance ($82-85B revenue) after one quarter as the deciding factor. The combined analyst view: Q1's $19.8B revenue print (+55.5% YoY) and Mounjaro's $8.66B quarter — which displaced Keytruda as the world's #1 best-selling drug — anchor the upside case while Foundayo's Week 5 acceleration removes the launch-trajectory overhang.

#eli-lilly #lly-stock #barclays #cantor-fitzgerald #motley-fool #analyst-targets #q1-2026
Industry

Motley Fool May 17: Could Lilly's Retatrutide 'Waylay Wegovy and Zap Zepbound' After TRIUMPH-1 and TRIUMPH-2 Readouts?

Motley Fool's May 17 analysis framed retatrutide — Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist — as the molecule positioned to displace both semaglutide (Wegovy) and tirzepatide (Zepbound) from the obesity therapeutics top spot. The thesis rests on TRIUMPH-1 (general obesity without T2D, 80 weeks, pivotal NDA-supporting trial) and TRIUMPH-2 (obesity + T2D) readouts expected Q2-Q3 2026. TRIUMPH-4 already reported a 28.7% mean weight reduction at the 12 mg dose at 68 weeks — well above the 21% standard Wegovy 2.4 mg and the 22.5% Zepbound 15 mg ceilings. If TRIUMPH-1 confirms the 25%+ weight-loss range, retatrutide's NDA filing follows in late 2026 / early 2027 with approval mid-2027. The full TRIUMPH program runs eight pivotal trials with >5,800 participants plus a separate 10,000-patient cardiovascular outcomes trial reading out in 2027.

#retatrutide #triumph-1 #triumph-2 #eli-lilly #next-generation #wegovy #zepbound
Research

Nature Biotechnology: Deep Peptide Recognition Profiling Decodes TCR Specificity for HLA-B27 Ankylosing Spondylitis Autoantigen Discovery

A Nature Biotechnology paper from a multi-institution collaboration introduced deep peptide recognition profiling (PRP) — a yeast-display platform integrated with protein-language models that maps T-cell receptor binding across the proteome for individual TCRs. Applied to HLA-B*27:05-restricted TCRs from patients with ankylosing spondylitis and acute anterior uveitis, the platform identified hundreds to over 6,000 unique peptide ligands per TCR and surfaced candidate autoantigens. Predicted binding scores correlated significantly with experimental T-cell activation across multiple TCRs. The model outperformed AlphaFold3 and tFold-TCR in predicting T-cell activation — meaningful for autoimmune-disease antigen discovery and personalized neoantigen cancer-vaccine design alike. The mechanistic implication: the CDR3β loop arches over the center of the HLA-B27-bound peptide and accounts for most contacts, with CDR3α positioned peripherally.

#nature-biotechnology #tcr-specificity #peptide-recognition #hla-b27 #ankylosing-spondylitis #autoantigen #neoantigen
Research

Discover Oncology 2026 Review: Antimicrobial Peptides as Anticancer Therapeutics — From Membrane Disruption to Vaccine Adjuvants

A 2026 Discover Oncology review (Springer Nature) consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics across three mechanistic categories: direct cytotoxicity through cancer-cell-membrane disruption (the same cationic-amphipathic chemistry that makes AMPs antibacterial works on the negatively charged outer leaflet of cancer-cell membranes), intracellular targeting of mitochondria and DNA replication, and use as vaccine adjuvants that boost immune responses to neoantigens. The review joins the May 2026 International Journal of Peptide Research piece on peptide cancer vaccines, the Frontiers in Medicine April 2026 anticancer AMP review, and the Frontiers in Bioinformatics March 2026 computational AMP discovery review as part of the AMP-as-cancer-therapeutic literature wave. Clinical translation remains limited: AMP-based cancer drugs in development are mostly preclinical or Phase 1.

#antimicrobial-peptides #anticancer-peptides #discover-oncology #vaccine-adjuvants #membrane-disruption #review-article
Clinical Trials

Retatrutide TRIUMPH-1 + TRIUMPH-2 Phase 3 Readouts Anticipated Q2-Q3 2026; Seven Total Phase 3 Trials Due This Year

Eli Lilly's TRIUMPH program for retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — has TRIUMPH-1 (general obesity without T2D, 80 weeks, 2,007 participants) and TRIUMPH-2 (obesity + T2D) reading out in Q2-Q3 2026. Both are pivotal for the planned NDA filing. The earlier TRIUMPH-4 readout in December 2025 delivered 28.7% mean weight loss at 68 weeks on 12 mg dosing with 75% knee osteoarthritis pain reduction. The full TRIUMPH program runs eight pivotal trials with >5,800 participants total: obesity, T2D, OSA, MASLD, knee OA, cardiovascular outcomes (TRIUMPH-OUTCOMES, ~10,000 patients reading out 2027), and dose-extension studies. A new safety signal noted in Phase 2 — a small uptick in mild-to-moderate hepatic enzyme elevations on 12 mg dosing — will be monitored carefully in Phase 3 readouts. Lilly's $4.5B Lebanon Indiana investment (announced May 6) targets retatrutide manufacturing capacity ahead of the 2027 approval window.

#retatrutide #triumph-1 #triumph-2 #triumph-outcomes #eli-lilly #phase-3 #lebanon-indiana
Industry

Foundayo TV Advertising Campaign Launches Late May — Brand-Awareness Push as Mid-May PBM Coverage Activates

Eli Lilly executives confirmed on the April 30 Q1 call that a full direct-to-consumer TV advertising campaign for Foundayo (orforglipron) launches in late May 2026, coinciding with the mid-May commercial access activation at two of the three largest US pharmacy benefit managers. The campaign emphasizes Foundayo's only-oral-GLP-1-without-food-or-water-restrictions positioning vs Novo's Wegovy pill, which requires fasting administration. Lilly previously held back consumer advertising through the first six weeks of launch to let PBM coverage scale before driving consumer prescription demand. Citi's May 8 IQVIA note flagged the upcoming campaign and PBM expansion as the catalysts for the Week 5+ trajectory acceleration that landed in the May 8 IQVIA print (10,248 scripts, +40% w/w).

#foundayo #orforglipron #tv-advertising #consumer-marketing #pbm-access #eli-lilly #launch-tracker
Research

AMR April-May 2026 Breakthrough Wave: AI-Designed Antimicrobial Peptides + Phage Therapy + Repurposed Drugs

April-May 2026 produced an unusual concentration of peer-reviewed advances against antimicrobial resistance, with peptide therapeutics anchoring much of the progress. The Frontiers in Bioinformatics March 17 review documented an AI/LLM pipeline (ProteoGPT) that produced 17 active peptides out of 18 designed (94.4% hit rate) in 48 days — collapsing the traditional discovery timeline. A Nature Microbiology generative-AI approach produced novel AMPs against multidrug-resistant bacteria with anti-inflammatory effects and minimal cytotoxic risk. Other April-May 2026 breakthroughs: Houston Methodist's CAMPER engineered against MRSA, the Manchester team's alternative ligase pathway to penicillins, and the Indian Institute of Technology Roorkee antibacterial peptide-drug conjugate against NDM-1/IMP-1 metallo-beta-lactamase pathogens. The combined wave signals the peptide-design stack has matured enough to compete directly with small-molecule antibiotic development.

#antimicrobial-resistance #amr #ai-drug-design #proteogpt #antimicrobial-peptides #april-may-2026
Industry

Wegovy Total Scripts Hit 446,000/Week with 40.5% Obesity GLP-1 Market Share — Injectable Strength Holds Despite First Pill Decline

Even with the first weekly Wegovy pill prescription decline since launch (~143K to ~137K week-ending May 8), the total Wegovy franchise (injectable + pill) climbed 1.3% week-over-week to approximately 446,000 prescriptions per the Fierce Pharma IQVIA tracker. Market share in the US obesity GLP-1 segment ticked up 0.1 percentage points to 40.5%. The injectable Wegovy 2.4 mg and Wegovy HD 7.2 mg formulations remain Novo's commercial anchor; the pill is the growth narrative. The 1.3% w/w injectable Wegovy growth aligns with Novo's H2 2026 international expansion plans and the EU approval expected before year-end. The data also confirms Zepbound (tirzepatide for obesity) continues to grow share faster than Wegovy on an absolute volume basis — the head-to-head dynamic that Cantor Fitzgerald and Barclays both cited in their May 5 LLY price target raises.

#wegovy #novo-nordisk #iqvia #market-share #obesity-glp-1 #weekly-tracker
Industry

ADA 2026 Scientific Sessions Three Weeks Out (June 5-8 New Orleans) — Peptide-Specific Slate Anchored on Retatrutide, AstraZeneca Eleglipron, Mazdutide

The American Diabetes Association 2026 Scientific Sessions opens in New Orleans on June 5 — three weeks out from today's Sunday digest. The peptide-relevant slate includes multiple Eli Lilly retatrutide TRIUMPH program presentations (some of the seven 2026 readouts expected to land at ADA), the Lilly + Indiana Biosciences Research Institute quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal-data poster on May 29, AstraZeneca's full Phase 2b VISTA and SOLSTICE data for eleglipron (formerly elecoglipron/AZD5004/ECC5004) after the April 29 topline, Innovent Biologics' mazdutide multi-program presentations (GLORY-2 18.55% weight loss, DREAMS-3 head-to-head vs semaglutide), Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data, and Pfizer berobenatide (MET-097i) VESPER program updates. ADA combined with the May 21 ASCO abstract drop set up a heavy June peptide news cycle.

#ada-2026 #retatrutide #eleglipron #mazdutide #survodutide #berobenatide #new-orleans